253 related articles for article (PubMed ID: 23942151)
1. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells.
Jeong GO; Shin SH; Seo EJ; Kwon YW; Heo SC; Kim KH; Yoon MS; Suh DS; Kim JH
Cell Physiol Biochem; 2013; 32(2):253-63. PubMed ID: 23942151
[TBL] [Abstract][Full Text] [Related]
2. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
3. Role of TAZ in Lysophosphatidic Acid-Induced Migration and Proliferation of Human Adipose-Derived Mesenchymal Stem Cells.
Mo WM; Kwon YW; Jang IH; Choi EJ; Kwon SM; Kim JH
Biomol Ther (Seoul); 2017 Jul; 25(4):354-361. PubMed ID: 28554198
[TBL] [Abstract][Full Text] [Related]
4. Role of LPA and the Hippo pathway on apoptosis in salivary gland epithelial cells.
Hwang SM; Jin M; Shin YH; Ki Choi S; Namkoong E; Kim M; Park MY; Park K
Exp Mol Med; 2014 Dec; 46(12):e125. PubMed ID: 25502757
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic Acid Induces ECM Production via Activation of the Mechanosensitive YAP/TAZ Transcriptional Pathway in Trabecular Meshwork Cells.
Ho LTY; Skiba N; Ullmer C; Rao PV
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1969-1984. PubMed ID: 29677358
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Jeong KJ; Park SY; Seo JH; Lee KB; Choi WS; Han JW; Kang JK; Park CG; Kim YK; Lee HY
Exp Mol Med; 2008 Dec; 40(6):607-16. PubMed ID: 19116446
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells.
Lee MJ; Jeon ES; Lee JS; Cho M; Suh DS; Chang CL; Kim JH
J Cell Biochem; 2008 May; 104(2):499-510. PubMed ID: 18027882
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Bian D; Su S; Mahanivong C; Cheng RK; Han Q; Pan ZK; Sun P; Huang S
Cancer Res; 2004 Jun; 64(12):4209-17. PubMed ID: 15205333
[TBL] [Abstract][Full Text] [Related]
10. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
11. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
13. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
[TBL] [Abstract][Full Text] [Related]
14. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
Yan L; Cai Q; Xu Y
Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
[TBL] [Abstract][Full Text] [Related]
16. The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration.
Bian D; Mahanivong C; Yu J; Frisch SM; Pan ZK; Ye RD; Huang S
Oncogene; 2006 Apr; 25(15):2234-44. PubMed ID: 16301993
[TBL] [Abstract][Full Text] [Related]
17. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
Yu X; Zhang Y; Chen H
BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
19. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract][Full Text] [Related]
20. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
Chen M; Towers LN; O'Connor KL
Am J Physiol Cell Physiol; 2007 May; 292(5):C1927-33. PubMed ID: 17496233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
